Haleos Labs Limited Upgraded to Hold as Technicals Improve and Valuation Attracts

Quality Assessment: Mixed Fundamentals with Stable Shareholding

Haleos Labs Limited’s quality rating remains moderate, reflected in its Mojo Score of 50.0 and a Mojo Grade of Hold. The company’s long-term fundamental strength is somewhat subdued, with an average Return on Capital Employed (ROCE) of 9.15%, which is below the ideal benchmark for robust capital efficiency in the pharmaceutical industry. Over the past five years, net sales have grown at a modest annual rate of 8.71%, while operating profit has increased at 13.38%, indicating steady but unspectacular growth.

Despite these moderate growth figures, the company’s capital structure is healthy, with a low debt-equity ratio of 0.34 times as of the half-year period, reducing financial risk. Additionally, the operating profit to interest coverage ratio stands at a strong 9.12 times, underscoring Haleos Labs’ ability to comfortably service its debt obligations. Promoters remain the majority shareholders, providing stability in ownership and strategic direction.

Valuation: Attractive Relative to Peers

Valuation metrics have played a significant role in the upgrade to Hold. Haleos Labs is currently trading at ₹1,295 per share, below its 52-week high of ₹1,680 and above its 52-week low of ₹956.05. The company’s Enterprise Value to Capital Employed ratio is a favourable 1.7, suggesting that the stock is trading at a discount relative to its peers’ historical valuations. This discount presents a potential value opportunity for investors seeking exposure to the pharmaceuticals sector at a reasonable price point.

Return on Capital Employed (ROCE) at 11% further supports the valuation case, indicating that the company is generating decent returns on its invested capital. However, investors should note that despite a 22.87% stock return over the past year, net profits have declined by 13.9%, signalling some underlying profitability pressures that warrant caution.

Financial Trend: Positive Quarterly Performance Amid Profitability Challenges

Haleos Labs reported a positive financial performance in Q3 FY25-26, with net sales reaching ₹94.78 crores, the highest quarterly figure recorded to date. This growth in sales is a positive indicator of demand strength and operational execution. The company’s operating profit margin remains healthy, supported by a strong operating profit to interest ratio of 9.12 times, which highlights efficient cost management and low financial leverage.

However, the year-to-date profit decline of 13.9% tempers enthusiasm, suggesting that while top-line growth is robust, bottom-line pressures persist. This mixed financial trend justifies the Hold rating, as investors weigh the potential for recovery against ongoing challenges in profitability.

Technical Analysis: Shift from Mildly Bearish to Mildly Bullish

The most significant catalyst for the rating upgrade is the improvement in technical indicators. The technical grade has shifted from mildly bearish to mildly bullish, reflecting a more positive market sentiment towards the stock. Daily moving averages have turned bullish, signalling upward momentum in the short term. Meanwhile, monthly Bollinger Bands have shifted to mildly bullish, suggesting potential for price expansion beyond recent ranges.

Other technical indicators present a mixed picture: the weekly MACD remains mildly bearish, while the monthly MACD also holds a mildly bearish stance. The Relative Strength Index (RSI) on a weekly basis shows no clear signal, but the monthly RSI remains bearish, indicating some caution among traders. The Dow Theory signals are split, mildly bearish on a weekly basis but mildly bullish monthly, reflecting a transitional phase in market trends.

Price action today saw the stock rise 1.57% to ₹1,295, with intraday highs touching ₹1,314.85 and lows at ₹1,212.10. Over the past week and month, Haleos Labs has outperformed the Sensex, delivering returns of 0.97% and 3.19% respectively, while the benchmark index declined by 3.84% and 5.61% over the same periods. This relative strength supports the technical upgrade and investor interest.

Comparative Market Performance

Over longer horizons, Haleos Labs has delivered market-beating returns. The stock has generated a 22.87% return over the past year, significantly outperforming the BSE500 index’s 11.97% return. Over three and five years, the stock’s returns have been even more impressive at 139.26% and 136.98% respectively, compared to the Sensex’s 32.28% and 55.60%. This strong relative performance underscores the company’s growth potential despite recent profit pressures.

However, investors should remain mindful of the company’s weak long-term fundamental strength and modest growth rates, which may limit upside in the absence of operational improvements or sector tailwinds.

Outlook and Investor Considerations

The upgrade of Haleos Labs Limited’s rating to Hold reflects a balanced view of the company’s prospects. Improved technical indicators and attractive valuation metrics provide a foundation for cautious optimism. The company’s strong quarterly sales and low leverage further support this stance.

Nevertheless, investors should be aware of the ongoing challenges in profitability and the relatively weak long-term fundamental growth. The stock’s performance relative to the broader market has been impressive, but sustaining this momentum will require operational improvements and favourable sector dynamics.

Given these factors, the Hold rating suggests that investors maintain their positions while monitoring upcoming quarterly results and technical signals for clearer directional cues.

Summary of Key Metrics:

• Mojo Score: 50.0 (Hold, upgraded from Sell on 4 March 2026)
• Market Cap Grade: 4
• Current Price: ₹1,295 (Day change +1.57%)
• 52-Week Range: ₹956.05 – ₹1,680
• Debt-Equity Ratio (HY): 0.34 times
• Operating Profit to Interest (Q): 9.12 times
• Net Sales (Q): ₹94.78 crores
• ROCE: 11%
• Enterprise Value to Capital Employed: 1.7
• 1-Year Stock Return: 22.87% vs Sensex 8.39%
• Profit Decline (1Y): -13.9%

Investors should continue to watch for developments in Haleos Labs’ operational performance and broader market trends to assess whether the Hold rating may be further upgraded or downgraded in the near term.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today